Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 111, Issue 1-2, 2008, Pages 13-17

  Chow, Louis Wing Cheong ^a,b,c   Yip, Adrian Yun San ^b   Loo, Wings Tjing Yung ^c   Lam, Chi Kei ^c   Toi, Masakazu ^b,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Organisation for Oncology and Translational Research   (Hong Kong)

^c UNIMED Medical Institute   (Hong Kong)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; Cyclooxygenase 2 inhibitor

Indexed keywords

CELECOXIB; EXEMESTANE; LETROZOLE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENERGY; FEMALE; HEART DISEASE; HISTOPATHOLOGY; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; HUMAN TISSUE; INSOMNIA; MAJOR CLINICAL STUDY; MEMORY DISORDER; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MYALGIA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; NEOADJUVANT THERAPY; POSTMENOPAUSE; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 48049084757     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.04.004     Document Type: Article

References (32)

1. Matsumine H., Hirato K., Yanaihara T., Tamada T., and Yoshida M. Aromatization by skeletal muscle. J. Clin. Endocrinol. Metab. 63 3 (1986) 717-720
2. Clemons M., and Goss P. Estrogen and the risk of breast cancer. New Engl. J. Med. 344 4 (2001) 276-285
3. Lu Q., Nakmura J., Savinov A., Yue W., Weisz J., Dabbs D.J., Wolz G., and Brodie A. Expression of aromatase protein and messenger ribonucleotide acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137 7 (1996) 3061-3068
4. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. New Engl. J. Med. 348 24 (2003) 2431-2442
5. Mouridsen H., and Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin. Oncol. 30 4 Suppl. 14 (2003) 33-45
6. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Jaenicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Chaudri-Ross H., Lang R., Wyld P., and Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21 11 (2003) 2101-2109
7. Lipton A., Ali S.M., Leitzel K., Demers L., Harvey H.A., Chaudri-Ross H.A., Brady C., Wyld P., and Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol. 21 10 (2003) 1967-1972
8. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., and Pater J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 19 (2003) 1793-1802
9. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., Dugardyn J.L., Nasurdi C., Mennel R.G., Cervek J., Fowst C., Polli A., di Salle E., Arkhipov A., Piscitelli G., Miller L.L., and Massimini G. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin. Breast Cancer 1 Suppl. 1 (2000) S15-S18
10. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 55 (1999) 7908-7916
11. Davies G., Salter J., Hills M., Martin L.A., Sacks N., and Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin. Cancer Res. 9 7 (2003) 2651-2656
12. Chiarugi V., Magnelli L., and Gallo O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Int. J. Mol. Med. 2 6 (1998) 715-719
13. Koki A.T., and Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9 2 Suppl. (2002) 28-35
14. Chow L.W.C., and Ho P. Hormonal receptor determination of 1052 Chinese breast cancers. J. Surg. Oncol. 75 3 (2002) 172-175
15. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 5 (2000) 1306-1311
16. Lu S., Zhang X., Badawi A.F., El-Sohemy A., and Archer M.C. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 184 1 (2002) 7-12
17. Hayward J.L., Carbone P.P., Heusen J.C., Kumaoka S., Segaloff A., and Rubens R.D. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer 35 3 (1977) 292-298
18. Common Terminology Criteria for Adverse Events v2.0 (CTCAE). National Cancer Institute. Available: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf (April 30, 1999).
19. Steele N., Zekri J., Coleman R., Leonard R., Dunn K., Bowman A., Manifold I., Kunkler I., Purohit O., and Cameron D. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 15 3 (2006) 426-430
20. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Cervek J., Fowst C., Polli A., Di Salle E., Massimini G., and Piscitelli G. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Results of a double-blind randomised phase III trial. Eur. J. Cancer 36 Suppl. 4 (2000) S86-S87
21. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 26 (2005) 2747-2757
22. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., Dugardyn J.L., Nasurdi C., Mennel R.G., Cervek J., Fowst C., Polli A., di Salle E., Arkhipov A., Piscitelli G., Miller L.L., and Massimini G. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J. Clin. Oncol. 18 7 (2000) 1399-1411
23. Simpson D., Curran M.P., and Perry C.M. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 64 11 (2004) 1213-1230
24. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., and Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10 1 Pt 2 (2004) S331-S336
25. 2 via cAMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 12 (1996) 5739-5742
26. Brodie A.M.H., Lu Q., Long B.J., Fulton A., Chen T., Macpherson N., DeJong P.C., Blankenstein M.A., Nortier J.W., Slee P.H., van de Ven J., van Gorp J.M., Elbers J.R., Schipper M.E., Blijham G.H., and Thijssen J.H. Aromatase and COX-2 expression in human breast cancer. J. Steroid Biochem. Mol. Biol. 79 1-5 (2001) 41-47
27. Brueggemeier R.W., Quinn A.L., Parrett M.L., Joarder F.S., Harris R.E., and Robertson F.M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140 1-2 (1999) 27-35
28. Singh-Ranger G., Kirkpatrick K.L., Clark G.M., and Mokbel K. Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr. Med. Res. Opin. 19 2 (2003) 131-134
29. Canney P.A., Machin M.A., and Curto J. A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur. J. Cancer 42 16 (2006) 2751-2756
30. European Organization for the Research and Treatment of Cancer (EORTC)-Investigational Drug Branch for Breast Cancer (IDBBC). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 14 9 (2003) 1391-1398
31. Leary A., and Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?. Br. J. Cancer 95 6 (2006) 661-666
32. Chow L.W.C., Cheng C.W.L., Wong J.L.N., and Toi M. Serum lipid profiles in patients receiving endocrine treatment for breast cancer-the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. Biomed. Pharmacother. 59 Suppl. 2 (2005) S302-S305